[go: up one dir, main page]

WO2004099371A3 - Methods of treating ischemic related conditions - Google Patents

Methods of treating ischemic related conditions Download PDF

Info

Publication number
WO2004099371A3
WO2004099371A3 PCT/US2004/013334 US2004013334W WO2004099371A3 WO 2004099371 A3 WO2004099371 A3 WO 2004099371A3 US 2004013334 W US2004013334 W US 2004013334W WO 2004099371 A3 WO2004099371 A3 WO 2004099371A3
Authority
WO
WIPO (PCT)
Prior art keywords
ischemia
hemorrhage
cerebral
methods
related conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/013334
Other languages
French (fr)
Other versions
WO2004099371A2 (en
Inventor
Bijan Almassian
Hossein Ghanbari
Michael Lebowitz
Weiying Pan
Zhi-Gang Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Pharmaceuticals Inc
Original Assignee
Panacea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals Inc filed Critical Panacea Pharmaceuticals Inc
Priority to AU2004236690A priority Critical patent/AU2004236690A1/en
Priority to JP2006513463A priority patent/JP2007527854A/en
Priority to EP04750963A priority patent/EP1626718A4/en
Priority to HK06114106.6A priority patent/HK1093892B/en
Priority to CA002525298A priority patent/CA2525298A1/en
Publication of WO2004099371A2 publication Critical patent/WO2004099371A2/en
Publication of WO2004099371A3 publication Critical patent/WO2004099371A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods of treating ischemia-related conditions by administering to a patient in need of such methods certain thiosemicarbazone compounds. Preferred embodiments of the present invention relates to methods of treating specific ischemia-related conditions, including but not limited to Alzheimer's disease, Parkinson's disease, Coronary artery bypass graft surgery, Global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage. hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, spinal stroke and spinal cord injury, diseases of cerebral blood vessels: e.g., atherosclerosis, vasculitis, Macular degeneration, myocardial infarction, cardiac ischemia and superaventicular tachyarrhytmia.
PCT/US2004/013334 2003-05-01 2004-04-30 Methods of treating ischemic related conditions Ceased WO2004099371A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004236690A AU2004236690A1 (en) 2003-05-01 2004-04-30 Methods of treating ischemic related conditions
JP2006513463A JP2007527854A (en) 2003-05-01 2004-04-30 Methods for treating ischemia-related conditions
EP04750963A EP1626718A4 (en) 2003-05-01 2004-04-30 Methods of treating ischemic related conditions
HK06114106.6A HK1093892B (en) 2003-05-01 2004-04-30 Compounds for treating ischemic related conditions
CA002525298A CA2525298A1 (en) 2003-05-01 2004-04-30 Methods of treating ischemic related conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46747303P 2003-05-01 2003-05-01
US60/467,473 2003-05-01
US55223104P 2004-03-10 2004-03-10
US60/552,231 2004-03-10

Publications (2)

Publication Number Publication Date
WO2004099371A2 WO2004099371A2 (en) 2004-11-18
WO2004099371A3 true WO2004099371A3 (en) 2005-01-27

Family

ID=33436731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013334 Ceased WO2004099371A2 (en) 2003-05-01 2004-04-30 Methods of treating ischemic related conditions

Country Status (6)

Country Link
US (2) US7456179B2 (en)
EP (1) EP1626718A4 (en)
JP (1) JP2007527854A (en)
AU (1) AU2004236690A1 (en)
CA (1) CA2525298A1 (en)
WO (1) WO2004099371A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004236690A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
US20060194810A1 (en) * 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions
DE102008020113A1 (en) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
DE102005019712A1 (en) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
DE102006050516A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New pyrazol-3-one compounds are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful e.g. to treat and/or prophylaxis heart-circulation diseases, heart failure, anemia, chronic kidney diseases and renal failure
DE102006050515A1 (en) * 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050513A1 (en) 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US8022072B2 (en) 2007-06-18 2011-09-20 Kaken Pharmaceutical Co., Ltd. Azolylmethylidenehydrazine derivative and use thereof
DE102010044131A1 (en) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituted sodium 1H-pyrazole-5-olate
US8684942B2 (en) 2011-05-25 2014-04-01 Siemens Medical Solutions Usa, Inc. System for cardiac impairment detection based on signal regularity
US10576069B2 (en) * 2013-03-14 2020-03-03 Panacea Pharmaceutical Inc. Treatment for chemotherapy-induced cognitive impairment
US20140271812A1 (en) 2013-03-14 2014-09-18 Panacea Pharmaceuticals Treatment for chemotherapy-induced cognitive impairment
US20160151339A1 (en) * 2013-03-21 2016-06-02 Hossein A. Ghanbari Treatment for Chemotherapy-Induced Peripheral Neuropathy
US20140287021A1 (en) * 2013-03-21 2014-09-25 Panacea Pharmaceuticals Treatment of chemotherapy-induced peripheral neuropathy
US20140363489A1 (en) * 2013-06-07 2014-12-11 Panacea Pharmaceuticals Treatment of eye disease
US20150110853A1 (en) * 2013-10-18 2015-04-23 Panacea Pharmaceuticals Treatment of radical prostatectomy-induced erectile dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721259A (en) * 1992-05-13 1998-02-24 Yale University Method of using 2-formylpyridine thiosemicarbazone compounds
US20020188011A1 (en) * 2001-04-20 2002-12-12 King Ivan C. Antiviral agents and methods of treating viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180831A (en) * 1990-08-10 1993-01-19 Georgia Tech Research Corporation Quaternary pyridinium compounds
JPH10114744A (en) * 1996-08-22 1998-05-06 Takeda Chem Ind Ltd Aminoguanidinehydrazone derivative, and its production and pharmaceutical preparation
SE9604348D0 (en) * 1996-11-26 1996-11-26 Wapharm Ab Use of hydroxyguanidines
DE69829048T2 (en) * 1997-04-22 2006-02-09 Euro-Celtique S.A. THE USE OF CARBOXYCLIC AND HETEROCYCLIC RESIDUES SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS
WO1999058666A1 (en) * 1998-05-08 1999-11-18 Astrazeneca Ab Potassium channel subunit
AU2004236690A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721259A (en) * 1992-05-13 1998-02-24 Yale University Method of using 2-formylpyridine thiosemicarbazone compounds
US20020188011A1 (en) * 2001-04-20 2002-12-12 King Ivan C. Antiviral agents and methods of treating viral infections

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Also Published As

Publication number Publication date
HK1093892A1 (en) 2007-03-16
US7456179B2 (en) 2008-11-25
JP2007527854A (en) 2007-10-04
WO2004099371A2 (en) 2004-11-18
CA2525298A1 (en) 2004-11-18
US20060160826A1 (en) 2006-07-20
US20090275587A1 (en) 2009-11-05
EP1626718A4 (en) 2010-05-05
AU2004236690A1 (en) 2004-11-18
EP1626718A2 (en) 2006-02-22

Similar Documents

Publication Publication Date Title
WO2004099371A3 (en) Methods of treating ischemic related conditions
WO2005004884A3 (en) Use of nitrite salts for the treatment of cardiovascular conditions
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
WO2008019144A3 (en) Threapeutic methods for treating vascular eye disorders with dll4 antagonists
WO2007062015A3 (en) Methods of treating ischemic related conditions
WO2006050359A3 (en) Pyridazine compounds and methods
Lazaro et al. Trapping and P2-P3 Posterior Inferior Cerebellar Artery Reanastomosis for Treatment of a Ruptured Fusiform Aneurysm: Application of Fourth-Generation Technique: 2-Dimensional Operative Video
WO2002102412A3 (en) Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
Girdauskas et al. Risk factors for stroke in cardiac surgery patients
CHIN et al. Peripheral intervention before bypass surgery in the elderly: feasible and effective, but is it necessary?
Isa et al. A case of hemodynamic brain infarction with postprandial hypotension
Bock-Lopez et al. HOPE FOR THE morbidly obese.
Woodiwiss et al. 4d. 08: Independent associations of galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample
Fletcher et al. Immediate Catheter Directed Thrombolysis for Thromboembolic Stroke during Carotid Endarterectomy
Munro Cardiac bypass without the pump
Whitaker Uses of the leukocyte-depleting filter
RU2159573C2 (en) Method for setting differential diagnosis of blood circulation state in exterior carotid and orbital artery beds
Hollenbeck et al. Atherosclerotic Renal Artery Stenosis: Clinical Data, Diagnosis and Treatment
Sanchez et al. Abstract No. 118 Genicular Artery Embolization for the Treatment of Persistent Knee Pain Following Joint Replacement Surgery
Mizuguchi et al. Surgery of the aortic arch
Goyen et al. Whole-Body MR Angiography for Arterial Disease Screening
Bruno et al. 4d. 06: Progression of carotid artery remodeling and stiffness in hypertensive patients: A prospective cohort study
Morris Activated protein C in the treatment of sepsis.
TW200741011A (en) Method for the diagnosis and treatment of cardiovascular diseases
Protopapas Pressure gradient in hemodynamics: Is it measured in units of pressure?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006513463

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2525298

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004236690

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004236690

Country of ref document: AU

Date of ref document: 20040430

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004236690

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004750963

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048187898

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004750963

Country of ref document: EP